Virtu Financial LLC Cuts Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Virtu Financial LLC reduced its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 39.4% during the third quarter, Holdings Channel reports. The institutional investor owned 22,986 shares of the company’s stock after selling 14,915 shares during the quarter. Virtu Financial LLC’s holdings in Aquestive Therapeutics were worth $114,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Victory Capital Management Inc. purchased a new stake in Aquestive Therapeutics during the 2nd quarter valued at about $27,000. nVerses Capital LLC purchased a new stake in shares of Aquestive Therapeutics during the third quarter valued at approximately $28,000. The Manufacturers Life Insurance Company bought a new position in shares of Aquestive Therapeutics in the second quarter worth approximately $76,000. Financial Advocates Investment Management increased its stake in shares of Aquestive Therapeutics by 70.0% in the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after buying an additional 14,000 shares during the period. Finally, Harvey Capital Management Inc. bought a new stake in Aquestive Therapeutics during the 3rd quarter valued at $88,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

NASDAQ:AQST opened at $3.64 on Friday. The firm has a market capitalization of $331.89 million, a P/E ratio of -8.09 and a beta of 2.62. Aquestive Therapeutics, Inc. has a one year low of $1.84 and a one year high of $6.23. The company’s 50-day simple moving average is $4.74 and its 200 day simple moving average is $4.06.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. On average, equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AQST. Leerink Partners raised their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Wednesday, November 6th. Cantor Fitzgerald began coverage on Aquestive Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $17.00 price objective for the company. Finally, JMP Securities reiterated a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $11.00.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.